Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Altimmune Inc (ALT)

Altimmune Inc (ALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026 GlobeNewswire - Wed May 6, 6:30AM CDT

GAITHERSBURG, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced...

ALT : 3.09 (+1.64%)
Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities GlobeNewswire - Mon Apr 27, 6:00AM CDT

$225 million funded at closing, with an additional $225 million warrant tranche Financing funds operations through anticipated Phase 3 MASH 52-week data readout Financing was led by Deep Track...

ALT : 3.09 (+1.64%)
Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities GlobeNewswire - Wed Apr 22, 10:25PM CDT

GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today...

ALT : 3.09 (+1.64%)
Altimmune Announces Proposed Underwritten Public Offering of Securities GlobeNewswire - Wed Apr 22, 3:19PM CDT

GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today...

ALT : 3.09 (+1.64%)
Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates GlobeNewswire - Thu Mar 5, 6:00AM CST

Initiation of Phase 3 MASH trial planned for 2026 Pemvidutide granted FDA Breakthrough Therapy Designation in MASH Topline data from RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder...

ALT : 3.09 (+1.64%)
Altimmune to Participate in Upcoming Investor Conferences GlobeNewswire - Mon Mar 2, 6:30AM CST

GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today...

ALT : 3.09 (+1.64%)
Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026 GlobeNewswire - Thu Feb 26, 6:30AM CST

GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced...

ALT : 3.09 (+1.64%)
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock GlobeNewswire - Thu Jan 29, 4:54PM CST

GAITHERSBURG, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced...

ALT : 3.09 (+1.64%)
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock GlobeNewswire - Tue Jan 27, 8:25PM CST

GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced...

ALT : 3.09 (+1.64%)
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH GlobeNewswire - Mon Jan 5, 6:30AM CST

GAITHERSBURG, Md., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing therapies that address serious liver diseases, today announced...

ALT : 3.09 (+1.64%)

Barchart Exclusives

Qualcomm Missed on Guidance. Investors Are Shrugging It Off as They Wait for Data Centers to Take QCOM Stock Higher. Barchart - Sat May 9, 4:00PM CDT
Qualcomm says the company has a growing opportunity in data. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.